SanBio, Inc., a scientific leader in regenerative medicine, today announced it has been granted a key patent by the United States Patent and Trademark Office (USPTO) covering its proprietary modified stem cells, SB623, for the treatment of retinal degeneration. SanBio developed SB623 to promote regenerative processes in the central nervous system and provide therapeutic options for debilitating neurological disorders, including retinal degeneration.
United States Patent No. 9,326,999 B2 was formally granted on May 3, 2016 and covers, among other things, the use of SB623 cells in treating retinal degeneration by enhancing photoreceptor function.
for more info: